{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT06625320","orgStudyIdInfo":{"id":"RMC-6236-302"},"organization":{"fullName":"Revolution Medicines, Inc.","class":"INDUSTRY"},"briefTitle":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","officialTitle":"RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","acronym":"RASolute 302"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-10-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-09-20","studyFirstSubmitQcDate":"2024-10-01","studyFirstPostDateStruct":{"date":"2024-10-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-05","lastUpdatePostDateStruct":{"date":"2025-12-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Revolution Medicines, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.","detailedDescription":"This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with RMC-6236 will improve progression free survival (PFS) or overall survival (OS) compared to Investigator's choice of standard of care chemotherapy in patients with metastatic PDAC who were previously treated with one prior line of therapy with 5-fluorouracil (5-FU) based or gemcitabine-based regimen.\n\nPatients will be randomized in a 1:1 ratio to receive RMC-6236 (Arm A) or Investigator's choice of standard of care chemotherapy (Arm B)."},"conditionsModule":{"conditions":["Pancreatic Cancer","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma"],"keywords":["Pancreatic Cancer","PDAC","Pancreatic Ductal Adenocarcinoma","RAS","KRAS","NRAS","HRAS","RAS Wild-Type","RAS Q61 Mutation","RAS G12 Mutation","RAS G13 Mutation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":501,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"RMC-6236","type":"EXPERIMENTAL","description":"Study drug","interventionNames":["Drug: RMC-6236"]},{"label":"Investigator's choice of standard of care therapy","type":"ACTIVE_COMPARATOR","description":"Patients randomized to Investigator's choice of standard of care chemotherapy will receive one of the following four treatments:\n\n* Gemcitabine and nab-paclitaxel (GnP)\n* Oxaliplatin, leucovorin, irinotecan, and 5-FU (Modified FOLFIRINOX: mFOLFIRINOX)\n* Liposomal irinotecan (Nal-IRI + 5-FU/LV)\n* Oxaliplatin, leucovorin and 5-FU IV (FOLFOX)","interventionNames":["Drug: Gemcitabine","Drug: nab-paclitaxel","Drug: Irinotecan","Drug: Liposomal irinotecan","Drug: 5-fluorouracil","Drug: leucovorin","Drug: Oxaliplatin"]}],"interventions":[{"type":"DRUG","name":"RMC-6236","description":"Oral Tablets","armGroupLabels":["RMC-6236"]},{"type":"DRUG","name":"Gemcitabine","description":"intravenous (IV) infusion","armGroupLabels":["Investigator's choice of standard of care therapy"]},{"type":"DRUG","name":"nab-paclitaxel","description":"IV infusion","armGroupLabels":["Investigator's choice of standard of care therapy"]},{"type":"DRUG","name":"Irinotecan","description":"IV infusion","armGroupLabels":["Investigator's choice of standard of care therapy"]},{"type":"DRUG","name":"Liposomal irinotecan","description":"IV infusion","armGroupLabels":["Investigator's choice of standard of care therapy"]},{"type":"DRUG","name":"5-fluorouracil","description":"IV infusion","armGroupLabels":["Investigator's choice of standard of care therapy"]},{"type":"DRUG","name":"leucovorin","description":"IV infusion","armGroupLabels":["Investigator's choice of standard of care therapy"]},{"type":"DRUG","name":"Oxaliplatin","description":"IV infusion","armGroupLabels":["Investigator's choice of standard of care therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression free survival (PFS) in the RAS G12-mutant population","description":"PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by blinded independent central review (BICR)","timeFrame":"Up to approximately 3 years"},{"measure":"Overall survival (OS) in the RAS G12-mutant population","description":"OS is defined as the time from randomization until death from any cause.","timeFrame":"Up to approximately 3 years"}],"secondaryOutcomes":[{"measure":"PFS in the all-patient population","description":"PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per RECIST v1.1 and as assessed by BICR.","timeFrame":"Up to approximately 3 years"},{"measure":"OS in the all-patient population","description":"OS is defined as the time from randomization until death from any cause.","timeFrame":"Up to approximately 3 years"},{"measure":"Objective response in the RAS G12 and all-patient populations","description":"Objective response is defined as partial response (PR) or completed response (CR) per RECIST v1.1, assessed by BICR.","timeFrame":"Up to approximately 3 years"},{"measure":"Time to deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26) in the RAS G12 and all-patient populations","description":"TTD is defined as the time from randomization to the first occurrence of deterioration as defined by a change of at least 10 points, or death, whichever occurs first, in each subscale in EORTC QLQ-PAN26.","timeFrame":"Up to approximately 3 years"},{"measure":"Time to deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in the RAS G12 and all-patient populations","description":"TTD is defined as the time from randomization to the first occurrence of deterioration as defined by a change of at least 10 points, or death, whichever occurs first, in each subscale and global QoL score in EORTC QLQ-C30.","timeFrame":"Up to approximately 3 years"},{"measure":"Objective response per investigator in RAS G12 and all- patient populations","description":"Objective response is defined as PR or CR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by the investigator.","timeFrame":"Up to approximately 3 years"},{"measure":"Duration of response (DOR) in RAS G12 and all-patient populations","description":"DOR is defined as time from first evidence of objective response (PR or CR) to disease progression or death due to any cause, whichever occurs first, as assessed by BICR and by the investigator.","timeFrame":"Up to approximately 3 years"},{"measure":"Time to response (TTR) in RAS G12 and all-patient populations","description":"TTR is defined as time from randomization to first evidence of objective response (PR or CR), as assessed by BICR and by the investigator.","timeFrame":"Up to approximately 3 years"},{"measure":"Percentage of patients with adverse events (AEs)","timeFrame":"Up to approximately 3 years"},{"measure":"Pharmacokinetics of RMC-6236 in RAS G12 and all-patient populations","description":"Pharmacokinetics are defined by blood concentrations of RMC-6236 over time.","timeFrame":"Up to approximately 3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed PDAC with metastatic disease.\n* Measurable disease per RECIST 1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation)\n* Documented RAS mutation status, either mutant or wild-type. RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).\n* History of or known central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study treatment\n* Major surgery within 4 weeks prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Study Director","affiliation":"Revolution Medicines","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Banner MD Anderson Cancer Center","city":"Gilbert","state":"Arizona","zip":"85234","country":"United States","geoPoint":{"lat":33.35283,"lon":-111.78903}},{"facility":"Mayo Clinic Cancer Center - Phoenix","city":"Phoenix","state":"Arizona","zip":"85054","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"City of Hope-Duarte","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"Cedars-Sinai Medical Center","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"UCLA","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"UC San Diego Health Moores Cancer Center","city":"San Diego","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Mission Hall UCSF","city":"San Francisco","state":"California","zip":"94158","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Rocky Mountain Cancer","city":"Aurora","state":"Colorado","zip":"80012","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Mayo Clinic Cancer Center - Florida","city":"Jacksonville","state":"Florida","zip":"32224","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"University of Miami Sylvester Comprehensive Cancer Center","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Cancer Care Centers of Brevard Inc","city":"Palm Bay","state":"Florida","zip":"32909","country":"United States","geoPoint":{"lat":28.03446,"lon":-80.58866}},{"facility":"Moffitt Cancer Center","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"The Queen's Medical Center","city":"Honolulu","state":"Hawaii","zip":"96813","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"The University of Chicago Medical Center","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Johns Hopkins","city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"University of Michigan","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Karmanos Cancer Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Mayo Clinic Cancer Center - Rochester","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"Washington University","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Roswell Park Cancer Institute","city":"Buffalo","state":"New York","zip":"14263","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"NYU Lagone Health","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10022","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Columbia University Medical Center","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Duke University Medical Center","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"University of Cincinnati Medical Center","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Stephenson Cancer Center","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Oregon Health and Science University","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Abramson Cancer Center Clinical Research Unit","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"UPMC Hillman Cancer Center","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Sarah Cannon Research Institute (Tennessee)","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Texas Oncology Sammons","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"MD Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Texas Oncology - Central South","city":"Irving","state":"Texas","zip":"75063","country":"United States","geoPoint":{"lat":32.81402,"lon":-96.94889}},{"facility":"Huntsman Cancer Institute","city":"Salt Lake City","state":"Utah","zip":"84112","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Virginia Cancer Specialists","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Fred Hutchinson Cancer Center","city":"Seattle","state":"Washington","zip":"98109","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Institut Paoli Calmettes","city":"Marseille","zip":"13009","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Centre Eugene Marquis","city":"Rennes","zip":"35042","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Hopital Paul Brousse","city":"Villejuif","zip":"94804","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Gustave Roussy","city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Charité Universitätsmedizin, Campus Berlin Mitte","city":"Berlin","zip":"13353","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Nationales Centrum fur","city":"Heidelberg","zip":"69120","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Universitatsklinikum Ulm, Zentru","city":"München","zip":"81377","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Universitatsklinikum Ulm","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Fondazione IRCCS Istituto Nazionale dei Tumori","city":"Milan","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"IEO-Istituto Europeo di Oncologia","city":"Milan","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"IOV-Istituto Oncologico","city":"Padua","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"Azienda Ospedaliera","city":"Pisa","zip":"56126","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"National Cancer Center","city":"Chiba","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"Aichi Cancer Center","city":"Nagoya","zip":"4648681","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Osaka International Cancer","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"National Cancer Center Hospital","city":"Tokyo","zip":"104-0045","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Cancer Institute Hospital of JFCR","city":"Tokyo","zip":"135-8550","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Kanagawa Cancer Center","city":"Yokohama","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Pan-American Center for Oncology Trials","city":"San Juan","zip":"00907","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"Hospital Unversitari","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital 12 de Octubre","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Clinica Universidad de Navarra","city":"Pamplona","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Hospital Clinico de Valencia","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D010190","term":"Pancreatic Neoplasms"}],"ancestors":[{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000093542","term":"Gemcitabine"},{"id":"C520255","term":"130-nm albumin-bound paclitaxel"},{"id":"D000077146","term":"Irinotecan"},{"id":"C584112","term":"irinotecan sucrosofate"},{"id":"D005472","term":"Fluorouracil"},{"id":"D002955","term":"Leucovorin"},{"id":"D000077150","term":"Oxaliplatin"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D002166","term":"Camptothecin"},{"id":"D000470","term":"Alkaloids"},{"id":"D014498","term":"Uracil"},{"id":"D011744","term":"Pyrimidinones"},{"id":"D005575","term":"Formyltetrahydrofolates"},{"id":"D013763","term":"Tetrahydrofolates"},{"id":"D005492","term":"Folic Acid"},{"id":"D011622","term":"Pterins"},{"id":"D011621","term":"Pteridines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D003067","term":"Coenzymes"},{"id":"D045762","term":"Enzymes and Coenzymes"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06040541","orgStudyIdInfo":{"id":"RMC-9805-001"},"organization":{"fullName":"Revolution Medicines, Inc.","class":"INDUSTRY"},"briefTitle":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","officialTitle":"Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors"},"statusModule":{"statusVerifiedDate":"2025-08","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-09-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-04-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-08-31","studyFirstSubmitQcDate":"2023-09-08","studyFirstPostDateStruct":{"date":"2023-09-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-08-27","lastUpdatePostDateStruct":{"date":"2025-08-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Revolution Medicines, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.","detailedDescription":"This is an open-label, multicenter, Phase 1/1b study of RMC-9805, a selective and orally bioavailable KRAS G12D(ON) inhibitor, in subjects with KRASG12D-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity. The study consists of two arms: RMC-9805 monotherapy arm and RMC-9805 plus RMC-6236 combination arm. Both arms consist of two parts: Part 1- dose exploration and Part 2- dose expansion."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors"],"keywords":["KRAS G12D (ON)","NSCLC","CRC","PDAC","Non-small Cell Lung Cancer","Lung Cancer","Colorectal Cancer","Colon Cancer","Pancreatic Cancer","Metastatic Cancer","Pancreatic Ductal Adenocarcinoma","Pancreatic Neoplasms","Colorectal Neoplasms","Gastrointestinal Neoplasms","KRAS","Colonic Neoplasms"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"The monotherapy arm of RMC-9805; the combination arm of RMC-9805 plus RMC-6236","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":604,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"RMC-9805 monotherapy arm","type":"EXPERIMENTAL","description":"Dose exploration and dose expansion","interventionNames":["Drug: RMC-9805"]},{"label":"RMC-9805 plus RMC-6236 combination arm","type":"EXPERIMENTAL","description":"Dose exploration and dose expansion","interventionNames":["Drug: RMC-9805","Drug: RMC-6236"]}],"interventions":[{"type":"DRUG","name":"RMC-9805","description":"Oral Tablets","armGroupLabels":["RMC-9805 monotherapy arm","RMC-9805 plus RMC-6236 combination arm"]},{"type":"DRUG","name":"RMC-6236","description":"Oral Tablets","armGroupLabels":["RMC-9805 plus RMC-6236 combination arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Adverse events","description":"Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs, and vital signs","timeFrame":"Up to 3 years"},{"measure":"Dose Limiting Toxicities","description":"Number of participants with Dose Limiting Toxicities (DLTs)","timeFrame":"21 days"}],"secondaryOutcomes":[{"measure":"Maximum Observed Blood Concentration (Cmax) of RMC-9805 as monotherapy and in combination with RMC-6236, and Cmax of RMC-6236 in combination with RMC-9805","description":"Cmax","timeFrame":"up to 21 weeks"},{"measure":"Time to Reach Maximum Blood Concentration (Tmax) of RMC-9805 as monotherapy and in combination with RMC-6236, and Tmax of RMC-6236 in combination with RMC-9805","description":"Tmax","timeFrame":"up to 21 weeks"},{"measure":"Area Under Blood Concentration Time Curve (AUC) of RMC-9805 as monotherapy and in combination with RMC-6236, and AUC of RMC-6236 in combination with RMC-9805","description":"AUC","timeFrame":"up to 21 weeks"},{"measure":"Ratio of accumulation of RMC-9805 from a single dose to steady state with repeated dosing as monotherapy and in combination with RMC-6236, and ratio of accumulation of RMC-6236 in combination with RMC-9805","description":"accumulation ratio","timeFrame":"up to 21 weeks"},{"measure":"Elimination Half-Life (t1/2) of RMC-9805 as monotherapy and in combination with RMC-6236, and t1/2 of RMC-6236 in combination with RMC-9805","description":"t1/2","timeFrame":"up to 21 weeks"},{"measure":"Overall Response Rate (ORR)","description":"Assess per RECIST v1.1","timeFrame":"up to 3 years"},{"measure":"Duration of Response (DOR)","description":"Assess per RECIST v1.1","timeFrame":"up to 3 years"},{"measure":"Disease Control Rate (DCR)","description":"Assess per RECIST v1.1","timeFrame":"up to 3 years"},{"measure":"Time to Response (TTR)","description":"Assess per RECIST v1.1","timeFrame":"up to 3 years"},{"measure":"Progression-Free Survival (PFS)","description":"Assess per RECIST v1.1","timeFrame":"up to 3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation\n* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage\n* ECOG performance status 0 or 1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Primary central nervous system (CNS) tumors\n* Known or suspected leptomeningeal or active brain metastases or spinal cord compression\n* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication\n* Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)\n\nOther inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Revolution Medicines, Inc.","role":"CONTACT","phone":"1-844-2-REVMED","email":"medinfo@RevMed.com"}],"overallOfficials":[{"name":"Revolution Medicines, Inc.","affiliation":"Revolution Medicines, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of California, Davis Comprehensive Cancer Center","status":"RECRUITING","city":"Sacramento","state":"California","zip":"95817","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Smilow Cancer Hospital (Yale University)","status":"RECRUITING","city":"New Haven","state":"Connecticut","zip":"06511","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Florida Cancer Specialists","status":"RECRUITING","city":"Sarasota","state":"Florida","zip":"34232","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"Lee Moffitt Cancer Center","status":"RECRUITING","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Johns Hopkins University","status":"RECRUITING","city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Massachusetts General Hospital","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Dana-Farber Cancer Institute","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"NYU Langone","status":"RECRUITING","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering Cancer Center","status":"RECRUITING","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Duke Cancer Center","status":"RECRUITING","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Carolina BioOncology Institute","status":"RECRUITING","city":"Huntersville","state":"North Carolina","zip":"28078","country":"United States","geoPoint":{"lat":35.41069,"lon":-80.84285}},{"facility":"The Christ Hospital","status":"RECRUITING","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Sarah Cannon Research Institute","status":"RECRUITING","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Sarah Cannon Research Institute at Mary Crowley","status":"RECRUITING","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"University of Texas, MD Anderson Cancer Center","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"START","status":"RECRUITING","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"NEXT Oncology Virginia","status":"RECRUITING","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}}]},"referencesModule":{"references":[{"pmid":"40705880","type":"DERIVED","citation":"Weller C, Burnett GL, Jiang L, Chakraborty S, Zhang D, Vita NA, Dilly J, Kim E, Maldonato B, Seamon K, Eilerts DF, Milin A, Marquez A, Spradlin J, Helland C, Gould A, Ziv TB, Dinh P, Steele SL, Wang Z, Mu Y, Chugh S, Feng H, Hennessey C, Wang J, Roth J, Rees M, Ronan M, Wolpin BM, Hahn WC, Holderfield M, Wang Z, Koltun ES, Singh M, Gill AL, Smith JAM, Aguirre AJ, Jiang J, Knox JE, Wildes D. A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors. Science. 2025 Jul 24;389(6758):eads0239. doi: 10.1126/science.ads0239. Epub 2025 Jul 24."},{"pmid":"40056080","type":"DERIVED","citation":"Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D015179","term":"Colorectal Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D003110","term":"Colonic Neoplasms"},{"id":"D010190","term":"Pancreatic Neoplasms"},{"id":"D009362","term":"Neoplasm Metastasis"},{"id":"D005770","term":"Gastrointestinal Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D007414","term":"Intestinal Neoplasms"},{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D003108","term":"Colonic Diseases"},{"id":"D007410","term":"Intestinal Diseases"},{"id":"D012002","term":"Rectal Diseases"},{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D009385","term":"Neoplastic Processes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false}
]}